Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy

Abstract Recombinant IL-2 has been used for the treatment of metastatic melanoma and renal cell carcinoma, and induced complete, durable tumor regression in some patients. ​However, its broader use in cancer immunotherapy has been limited by severe toxicity. Here, we describe the development of REGN10597, a PD-1-targeted, receptor-masked IL-2 immunocytokine with attenuated systemic IL-2 activity but maintained capacity to engage endogenous IL-2Ra on PD-1+ T cells. We will share preclinical data on in vitro characterization as well as in vivo efficacy and toxicity studies of REGN10597. Citation Format: Jiaxi Wu, Nicolin Bloch, Aaron Chang, Ramandeep Bhavsar, Qingqing Wang, Supriya Patel, Vidur Garg, Hassan Shakil, Michael Amatulli, Drew Dudgeon, Yuetian Yan, Shunhai Wang, Willy Ramos, Pamela Krueger, Kristin Vazzana, Alison Crawford, Jacqueline Idun, Corinne Decker, David DiLillo, Samira Chandwani, Tammy Huang, Jessica Kirshner, Chungguang Guo, Lynn Macdonald, Erica Ullman, Aynur Hermann, William Olson, Samuel Davis, John Lin, Eric Smith, Tong Zhang. REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr IA012.